1. Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases

   • Zhe-Bin Liu
   • Nader E. Ezzedine
   • Jenny C. Chang

   Preclinical study 06 August 2019 Pages: 251 - 261

   

2. Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer

   • Jichao He
   • Ronan P. McLaughlin
   • Bob van de Water

   Preclinical study Open access 06 August 2019 Pages: 263 - 274

   

3. HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor

   • Yuanyuan Liu
   • Shafei Wu
   • Xuan Zeng

   Preclinical study Open access 06 August 2019 Pages: 275 - 281

   

4. Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer

   • Akira I. Hida
   • Takahiro Watanabe
   • Akihide Tanimoto

   Preclinical study 12 August 2019 Pages: 283 - 294

   

5. Evaluation of phospho-histone H3 in Asian triple-negative breast cancer using multiplex immunofluorescence

   • Chi Peng Timothy Lai
   • Joe Poh Sheng Yeong
   • Puay Hoon Tan

   Preclinical study 13 August 2019 Pages: 295 - 305

   

6. Genomic landscape of ductal carcinoma in situ and association with progression

   • Chieh-Yu Lin
   • Sujay Vennam
   • Robert B. West

   Preclinical study 17 August 2019 Pages: 307 - 316

   

7. Gene expression analysis to detect disseminated tumor cells in the bone marrow of triple-negative breast cancer patients predicts metastatic relapse

   • Chidananda M. Siddappa
   • Sreeraj G. Pillai
   • Rebecca Aft

   Preclinical study Open access 20 August 2019 Pages: 317 - 325

   

8. A randomized, double-blind, window of opportunity trial evaluating the effects of chloroquine in breast cancer patients

   • Angel Arnaout
   • Susan J. Robertson
   • Mark Clemons

   Clinical trial 07 August 2019 Pages: 327 - 335

   

9. A multicentre, randomized pilot trial comparing vascular access strategies for early stage breast cancer patients receiving non-trastuzumab containing chemotherapy

   • Andrew Robinson
   • Carol Stober
   • the REaCT investigators

   Clinical trial 07 August 2019 Pages: 337 - 345

   

10. Randomized window of opportunity trial evaluating high-dose vitamin D in breast cancer patients

    • Angel Arnaout
    • Susan Robertson
    • Mark Clemons

    Clinical trial 09 August 2019 Pages: 347 - 356

    

11. Phase II randomized controlled trial of hypnosis versus progressive muscle relaxation for body image after breast or gynecologic cancer

    • Debra L. Barton
    • Trevor M. Brooks
    • Catherine H. Van Poznak

    Clinical trial 09 August 2019 Pages: 357 - 365

    

12. Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11)

    • Ji-Yeon Kim
    • Eunjin Lee
    • the Breast Cancer Committee of the Korean Cancer Study Group

    Clinical trial 12 August 2019 Pages: 367 - 377

    

13. Marital status is an independent prognostic factor in inflammatory breast cancer patients: an analysis of the surveillance, epidemiology, and end results database

    • Yan-ling Liu
    • Dun-wei Wang
    • Zhi-wen Li

    Clinical trial Open access 14 August 2019 Pages: 379 - 388

    

14. Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination

    • Sandra M. Swain
    • Gong Tang
    • Norman Wolmark

    Clinical trial Open access 19 August 2019 Pages: 389 - 399

    

15. Long-term outcome with targeted therapy in advanced/metastatic HER2-positive breast cancer: The Royal Marsden experience

    • Nicolò Matteo Luca Battisti
    • Daniel Tong
    • Ian Smith

    Clinical trial 20 August 2019 Pages: 401 - 408

    

16. Reliability of preoperative breast biopsies showing ductal carcinoma in situ and implications for non-operative treatment: a cohort study

    • Gurdeep S. Mannu
    • Emma J. Groen
    • Jelle Wesseling

    Epidemiology Open access 06 August 2019 Pages: 409 - 418

    

17. Utilization, duration, and outcomes of neoadjuvant endocrine therapy in the United States

    • Ashley C. Pariser
    • Tannaz Sedghi
    • Sarah S. Mougalian

    Epidemiology 10 August 2019 Pages: 419 - 426

    

18. Allelic modification of breast cancer risk in women with an NBN mutation

    • Bogna Rusak
    • Wojciech Kluźniak
    • the Polish Hereditary Breast Cancer Consortium

    Epidemiology 13 August 2019 Pages: 427 - 431

19. Differences in breast cancer outcomes amongst Black US-born and Caribbean-born immigrants

    • Priscila Barreto-Coelho
    • Danielle Cerbon
    • Sophia H. L. George

    Epidemiology 14 August 2019 Pages: 433 - 440

    

20. Time-to-surgery and overall survival after breast cancer diagnosis in a universal health system

    • Yvonne L. Eaglehouse
    • Matthew W. Georg
    • Kangmin Zhu

    Epidemiology 14 August 2019 Pages: 441 - 450

    

21. Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes

    • Giuseppe Viale
    • Amy E. Hanlon Newell
    • Patrick Maisonneuve

    Epidemiology Open access 17 August 2019 Pages: 451 - 458

    

22. Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer

    • Christine Lundgren
    • Pär-Ola Bendahl
    • Maria Ekholm

    Epidemiology Open access 20 August 2019 Pages: 459 - 467

    

23. Rationale for evaluating breast cancers of Lynch syndrome patients for mismatch repair gene expression

    • Steven Sorscher

    Brief Report 07 August 2019 Pages: 469 - 471

24. Effect of early adverse events resulting in ado-trastuzumab emtansine dose adjustments on survival outcomes of HER2+ advanced breast cancer patients

    • Ethan Tang
    • Andrew Rowland
    • Ashley M. Hopkins

    Brief Report 09 August 2019 Pages: 473 - 477

    

25. Precision medicine: PI3K targeting in advanced breast cancer

    • Andrea Rocca
    • Elisabetta Melegari
    • Michela Palleschi

    Letter to the Editor 19 August 2019 Pages: 479 - 479

26. Letter regarding Sopik V et al. entitled “Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ”

    • Xiangyu Wang
    • Xiangyi Kong
    • Jing Wang

    Letter to the Editor 20 August 2019 Pages: 481 - 482